ArticleFrontiers in cellular and infection microbiology2024
Characterization and efficacy against carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- AUBFM01 Phage as a Therapeutic Candidate Against MDRMicroorganisms · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- Phage vB_AbaM_MU1 for biocontrol of carbapenem-resistant Acinetobacter baumannii (CRAB) isolated from wound infection.Virology journal · 2026Article
- The Role of Genomics in Advancing and Standardising Bacteriophage Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- Characterization of phage AbpL with a terminally redundant genome and its therapeutic potential against drug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Isolation and characterization of two novel phages with lytic activity against multidrug-resistant Acinetobacter baumannii strains: potential for phage therapy.Scientific reports · 2025Article
- Characterization and genome analyses of the novel phages targeting extraintestinal Escherichia coli clones ST131 and ST410.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage.Applied microbiology and biotechnology · 2025Article
- Characterization of a lytic phage and its efficacy against carbapenem-resistant Pseudomonas aeruginosa infection in mice.BMC microbiology · 2025Article
- Genomic and Functional Characterization of Novel Phages Targeting Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.AMB Express · 2025Review
- Bacteriophage and Phage-Encoded Depolymerase Exhibit Antibacterial Activity Against K9-TypeViruses · 2025Article
- Geographic variation in abundance and diversity ofFrontiers in microbiology · 2025Article
- Identification of multi-drug resistantFrontiers in microbiology · 2025Article
- Isolation, characterization and therapeutic evaluation of phage HHU1 against K2Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.